GeneDx Holdings (WGS), Why Is This Fresh Development Drawing Attention?
GeneDx Holdings (WGS) has caught investor attention after launching a new online pathway for exome testing that lets U.S. families start clinician-guided genetic tests for children with developmental delay, intellectual disability, or epilepsy directly from GeneDx.com.
See our latest analysis for GeneDx Holdings.
The launch of GeneDx Holdings’ online exome pathway comes at a time when the stock has shown strong recent momentum, with a 30 day share price return of 18.05% and a 90 day share price return of 91.61%. However, the year to date share price return is still down 40.98%, the 1 year total shareholder return is down 38.21%, and the 3 year total shareholder return is very large.
If you are interested in how other healthcare focused AI companies are trading, this is a good moment to scan the market using the 44 healthcare AI stocks
After a sharp rebound in GeneDx Holdings, the stock still trades at a sizeable discount to both analyst targets and one intrinsic value estimate. Is that a genuine mispricing, or is the market simply pricing in ongoing caution about losses and execution risk?
Most Popular Narrative: 1% Overvalued
At a last close of $78.08 versus a narrative fair value of $77, the current GeneDx Holdings share price is only slightly above that estimate, which puts more focus on the story and assumptions behind that fair value.
Rapid expansion into new and underpenetrated markets including general pediatrics (driven by American Academy of Pediatrics guidelines), NICU, and additional pediatric specialties positions GeneDx for substantial future volume and revenue growth as adoption of genomics as a frontline diagnostic tool accelerates.
Read the complete narrative. Read the complete narrative.
Want to see what sits underneath that almost one to one match between price and fair value? The narrative leans heavily on faster revenue, a swing from losses to profits, and a rich future earnings multiple. Curious how those moving pieces combine into a single number and what has to go right for GeneDx Holdings to reach it.
Result: Fair Value of $77 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in GeneDx Holdings still need to weigh reimbursement pressures and competition, which could slow adoption and undermine the optimistic AI driven growth story.
Find out about the key risks to this GeneDx Holdings narrative.
Another View: SWS DCF Model Points To Deep Undervaluation
While the popular narrative pegs GeneDx Holdings as about 1% overvalued at $78.08 versus a $77 fair value, the Simply Wall St DCF model presents a different perspective. It suggests the stock trades about 67% below an estimated future cash flow value of $236.93. This raises the question of whether the market is underpricing long-term cash generation, or whether the DCF assumptions are too optimistic for a business that is still loss making.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out GeneDx Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Given the mixed sentiment around GeneDx Holdings, it makes sense to look directly at the underlying data and move quickly to form your own view with the 2 key rewards
Looking for more investment ideas beyond GeneDx Holdings?
Do not stop with GeneDx Holdings. Broaden your watchlist now using focused stock ideas that line up with different risk levels, balance sheets, and return profiles.
- Target value opportunities that combine quality and price by scanning the 50 high quality undervalued stocks.
- Prioritise staying power and financial strength by filtering for companies in the solid balance sheet and fundamentals stocks screener (50 results).
- Spot lesser known prospects before others do by running the screener containing 18 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com